A Randomized Phase 2 Study of Losartan and Nivolumab in Combination with FOLFIRINOX and SBRT in Localized Pancreatic Cancer (Stand up to Cancer)

Brief description of study

This multi-center, open-label, rando ized Phase II study will evaluate the effectiveness of the addition of the angiotension II type receptor blocker Losartan, or the combination of losartan and immunotherapy (nivolumab) to FOLFIRINOX (leucovorin, 5-FU, irinotecan, oxaliplatin) followed by SBRT (Stereotactic Body Radiation Therapy) and surgery. This will be benchmarked against a control arm of FOLFIRINOX followed by SBRT and surgery. An exploratory arm (not randomized) will be included for patients already on an ACE/ARB (angiotensin-converting enzyme inhibitor / angiotensin-receptor blocker). The study will include borderline resectable and locally advanced pancreatic cancers.


Clinical Study Identifier: s18-00791
ClinicalTrials.gov Identifier: NCT03563248
Principal Investigator: Paul E. Oberstein
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.